Meta Pharmacy Services (Barclay Luke & Pillai Specialty Pharmacy PLLC), Las Vegas, NV
Is Meta Pharmacy Services (Barclay Luke & Pillai Specialty Pharmacy PLLC) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Meta Pharmacy Services (Barclay Luke & Pillai Specialty Pharmacy PLLC) hold a Nevada pharmacy license?
State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search. The Colorado State Board of Pharmacy also lists nonresident license OSP 7546 for Meta Pharmacy Services, LLC, Las Vegas, NV, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054023118 for META PHARMACY SERVICES LLC, LAS VEGAS, NV, status ACTIVE and license 054021457 for META PHARMACY SERVICES LLC, LAS VEGAS, NV, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0004217 for META PHARMACY SERVICES, LAS VEGAS, NV, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0013252 for Meta Pharmacy Services, LLC, LAS VEGAS, NV, status Active and license A9-0012952 for BARCLAY LUKE & PILLAI SPECIALTY PHARMACY PLLC, LAS VEGAS, NV, status Expired, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012981 for Meta Pharmacy Services, LLC, Las Vegas, NV, status Active, as of Nov 10, 2026.
Has Meta Pharmacy Services (Barclay Luke & Pillai Specialty Pharmacy PLLC) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Mar 15, 2024), 1 untitled letter (Sep 14, 2023), 1 state referral letter (Mar 15, 2024) and 1 FMD-145 letter (Mar 15, 2024) for Meta Pharmacy Services (Barclay Luke & Pillai Specialty Pharmacy PLLC). State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Barclay Luke & Pillai Specialty Pharmacy PLLC; Meta Pharmacy Services
- Location
- Las Vegas, NV
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Mar 15, 2024
- FDA Data Dashboard inspections
- 3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 18 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Barclay Luke & Pillai Specialty Pharmacy PLLC (dba Meta Pharmacy Services), a 503A facility, with 6 dated actions.
| Document | |||
|---|---|---|---|
| Mar 15, 2024 | State referral letter | State Referral Letter Issued 03/15/2024 | FDA copy (archived) |
| Mar 15, 2024 | Warning letter close-out | Warning Letter Closeout Issued 03/15/2024 | FDA copy (archived) |
| Mar 15, 2024 | FMD-145 letter | FMD-145 Letter Issued 03/15/2024 | Not linked by FDA |
| Sep 14, 2023 | Untitled letter | Untitled Letter Issued 09/14/2023 | FDA copy (archived) |
| Dec 9, 2022 | Amended Form 483 | Amended 483 Issued 12/9/2022 | FDA copy (archived) |
| Dec 9, 2022 | Form 483 | 483 Issued 12/09/2022 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Barclay, Luke, & Pillai Specialty Pharmacy, PLLC, Las Vegas, NV (FEI number 3011888866), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Dec 9, 2022 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011888866 | 1192411 |
| Dec 14, 2018 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011888866 | 1074624 |
| Dec 20, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011888866 | 997588 |
Form 483s FDA has published for this site
- Dec 9, 2022: Form 483 to Barclay, Luke, & Pillai Specialty Pharmacy, PLLC, published Feb 23, 2023. fda.gov
- Dec 14, 2018: Form 483 to Barclay, Luke, & Pillai Specialty Pharmacy, PLLC, published Apr 30, 2019. fda.gov
- Feb 28, 2017: Form 483 to Barclay, Luke, & Pillai Specialty Pharmacy, PLLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 18 numbered observations in all, across 2 inspections ending Dec 14, 2018 to Dec 9, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 28, 2022 to Dec 9, 2022: 7 observations
- Firm on the cover
- Barclay, Luke, & Pillai Specialty Pharmacy, PLLC, 8352 W Warm Springs Rd, Suit e 120, Las Vegas, NV 89113-3629
- FEI number
- 3011888866
- Establishment type on the cover
- Producer of Sterile and Non-Sterile Drug Products
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
The ISO 5 classified aseptic processing areas had difficult to clean and visibly dirty equipment or surface.
Specifically,
The ISO 5 hoods in your sterile non-hazardous cleanroom, both of which are used to produce drug products purported to be sterile, were observed to contain visibly dirty surfaces during multiple walkthroughs between 11/28/22 and 12/02/22. Those observations include, but are not limited to the following:
a) An accumulation of a fibrous material around the edges of the holes along the work surface front edge, work surface back edge, and side walls of the <Redacted B4> hood.
b) A paper equipment ID sticker stuck to the left wall of the ISO 5 workspace inside the <Redacted B4> hood, with visible discoloration underneath the tape covering the sticker.
c) Seven red-brown apparent splatter marks on the surface of the <Redacted B4> HEPA filter inside the back wall of the ISO 5 <Redacted B4> laminar flow hood (LFH).
d) An approximate 8" vertical crack in the right side of the plastic sash of the <Redacted B4> hood. ...
Observation 2
Non-microbial contamination was observed in your production area.
Specifically,
Your sterile non-hazardous and sterile hazardous cleanrooms, both of which are used to produce drug products purported to be sterile, were observed to contain several difficult to clean, particle generating, or visibly dirty surfaces during multiple walkthroughs between 11/28/22 and 12/02/22. Those observations include, but are not limited to the following:
a) Apparent rust on multiple metal surfaces in the sterile non-hazardous cleanroom, including wheel casters supporting the <Redacted B4> refrigerator in the southwest comer of the room, wheel casters on a metal cart supporting a <Redacted B4> positioned adjacent to the <Redacted B4> refrigerator, metal hinges on a <Redacted B4>, and a bolt in the right side of the <Redacted B4> hood outer casing. ...
Observation 3
You produced hazardous drugs without providing adequate containment to prevent cross-contamination.
Specifically,
Your records used to document the pressure differential between the ISO 7 sterile hazardous cleanroom and the adjacent ISO 7 anteroom showed that the pressure differential between these two rooms was below your established specification of <Redacted B4> and therefore did not pass the check during 6 <Redacted B4> checks <Redacted B4> between 10/10/22 and 11/30/22, with the exception of 11/02/22. The ISO 7 sterile hazardous cleanroom and the adjacent ISO 7 anteroom were both regularly used in the production of sterile drugs throughout this period.
The differential pressure gradient between the anteroom and sterile hazardous cleanroom is designed to prevent the movement of air from the sterile hazardous cleanroom into the anteroom, and the recorded measurements show a pervasive differential below the lower limit of the pressure differential designed to maintain this separation. ...
Observation 4
Unsealed, loose ceiling tiles were observed in your cleanroom.
Specifically,
a) On 11/28/22, an unsealed ceiling tile was observed directly above the ISO 5 biosafety cabinet (BSC) in your ISO 7 sterile hazardous cleanroom.
b) While witnessing the cleaning of your ISO 7 sterile non-hazardous cleanroom on 12/02/22,
I observed that the ceiling tile in the northwestern corner of this room became pushed up out of t he frame in which it was seated while being wiped with a fabric mop head. On 11/29/22, the <Reda cted B4> h ood installed in this room was observed to be used in the production of 100 mL of Nia cmarmde 100 mg/mL injectable solution, lot 112922JF@<Redacted B4>
Observation 5
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically,
Your firm did not perform analytical testing on drug products lots produced by your firm to ensure the identity and strength of active ingredients prior to distribution, including the following:
a) Lidocaine 5% Topical Solution, 3000 mL, produced on 09/14/22 and 10/13/22 to fill Rx <Redacted B4> on 9/13/22 and 10/17 /22 respectively.
b) Dyclonine 10 mg/mL oral suspension, 480 mL, produced on 09/14/22 and used to fill Rx <Redacted B4> on 09/14/22.
Observation 6
The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.
Specifically,
a) Your firm did not perform identity or any other analytical testing on multiple raw materials used in the production of two 3000 mL lots of Lidocaine 5% Topical Solution, produced on 09/14/22 and 10/13/22 to fill Rx <Redacted B4> on 9/13/22 and 10/17 /22 respectively, including the following:
b) Your firm did not perform identity or any other analytical testing on multiple raw materials used in the production Qf a 480 mL lot of Dyclonine 10 mg/mL oral suspension, produced on 09/14/22 and used to fill Rx <Redacted B4> on 09/14/22, including the following:
• Dyclonine HCI, NDC <Redacted B4> exp 03/19/24
• Menthol, NDC <Redacted B4> February 2023
• Polysorbate, NDC <Redacted B4> July 2023
• Propylene Glycol, NDC <Redacted B4> exp 02/23/24
Observation 7
Media fills do not adequately simulate the most challenging or stressful conditions.
Specifically, the media fill operation used to re-qualify one of your technicians for sterile operations on 08/24/22 consisted of the preparation of three 5 mL bottles of Tryptic Soy Broth 3% Solution plus a 5 mL control bottle. On 12/05/22, that same technician stated that your firm produces lots that are as large as <Redacted B4> 50 mL vials of sterile drug product. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.
Inspection Nov 27, 2018 to Dec 14, 2018: 11 observations
- Firm on the cover
- Barclay, Luke, & Pillai Specialty, 8352 W Warm Springs Rd Ste 120 Pharmacy, PLLC, Las Vegas, NV 89113- 3629 Producer o f Sterile and Non- Sterile Drugs
- FEI number
- 3011888866
- FDA district office on the cover
- 1431 Harbor Bay Parkway Alameda, CA 94502-7070
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically,
A. Your fir m's REDACTED (b)(4) is inadequate in that you did not obtain the recommended REDACTED (b)(4)REDACTED (b)(4) as specified on the accompanied brochure during the REDACTED (b)(4) test. Your test resulted REDACTED (b)(4) than recommended. Your firm used a REDACTED (b)(4) drug product produced by your firm. The recommend REDACTED (b)(4) for this type of REDACTED (b)(4) was REDACTED (b)(4). However, during the REDACTED (b)(4) I test of the following drug products that used the same type and lot number of the REDACTED (b)(4) the folloing was observed: 1) Meta PT Eye Drops Lot# 102918 REDACTED (b)(4) with REDACTED (b)(4) test result of REDACTED (b)(4). This product has a BUD of 200 days. 2) Testosterone Cypionate 200 mg/mL in Grapeseed Oil for IM Injection Lot# 092418 REDACTED (b)(4) with REDACTED (b)(4) test result of REDACTED (b)(4) This product has a BUD of 100 days. J J
You r firm's REDACTED (b) (4 ) is inadequate in that yo u did not obtain the recommended REDACTED (b) (4)REDACTED (b)( ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A. Your firm does not perform environmental and personnel monitoring during the production of
sterile diug product s. Your firm conducts environmental monitoring including viable, non-viable, and surface monitoring on REDACTED (b)(4) basis along with the cleanroom, anteroom, and ISO 5 laminar flow hood certifications. Your firm conducts personnel fingertip monitoring every REDACTED (b)(4) following REDACTED (b)(4) test.
B. Your firm has not performed the REDACTED (b)(4) certification of ISO 7 cleanrooms, ISO 7 anteroom, and ISO 5 laminar flow hood. The last certification was conducted May 8, 2018. J
Observation 3
You did not have a HEP A filter over the area to which sterile product was exposed.
Specifically,
Your firm produces and packs pellets purportedly to be sterile within the non-sterile area prior to the sterilization process. This room is a negative pressure and unclassified room. The firm produces the following pellet dmg products:
A. Testosterone Sterile Pellets B. Estradiol Sterile Pellets C. Progesterone Sterile Pellets D. Naltrexone Sterile Pellets
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the to produce aseptic conditions.
Specifically,
Your firm uses a non-sterile lint free wipe and non-sterile mop head for cleaning the ISO 5 laminar flow hood before and after the production.
Observation 5
Clothing of personnel engaged in the of diug products is not appropriate for the duties they perfo1m .
Specifically,
A. On 11/ 27/2018, Ope rator REDACTED (b)( 6) was ob served having e xpose d skin arou nd the goggle while producing Methyl cobalamin (Bl2 ) 12.5 mg/mL IM In j Lot# 112718 REDACTED (b)(6) an d Glutathione 20% Injection Lot# 112718 REDACTED (b)(6)
B. On 1 2/06/2018 , Op er at or REDACTED (b)(6 ) was obs erve d having expos ed skin a ro und the g og gle whi le pro ducing High dose vitamin C Myer Cocktail IV admixture Lot# 1 20618REDACTED (b)(6)
Observation 6
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already disti-ibuted.
Specifically,
Your firm did not investigate the discrepancy between the REDACTED (b)(4) test results obtained during the test and the REDACTED (b)(4) manufacturer recommended REDACTED (b)(4) You ob tained REDACTED (b)(4) test result s as specified below. The recom mend REDACTED (b)(4)
A. Meta PT Eye Drops Lot # 102918 REDACTED (b)( 4) with REDACTED (b)(4) test result of REDACTED (b)(4). This product has a BUD of 200 days.
B. Testostero rne C
ypi onate 200 mg/m L in G rapeseed Oil for IM I nje ction Lot # 09 24 18 REDACTED (b)(4) wi th REDACTED (b)(4) test resu lt of REDACTED (b)(4) This product has a BUD of 100 days
Observation 7
Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the diug product.
Specifically,
A. Your firm does not depyrogenate the glassware including REDACTED (b)(4) that are used to weig
h non-sterile bulk diug substance and mix all components before sterilization inside the ISO 5 la minar flow hood. The REDACTED (b)(4) are used in drug products
su ch as 1) Meta PT Ey e D rops 2) Testosterone Cypionate 200mg/mL in Grapeseed Oil for IM Injection
B. Your firm has not determined the hold time of the cleaned REDACTED (b)(4) that are stored inside th
e ISO 7 ante room. These REDACTED ( b)(4) a re stored unc overed a n exposed to th e ISO 7 a nteroom environment. They can be stored on the cart indefinitely before use. The REDACTED (b)(4) are used in drug products such as 1) Meta PT Eye Drops 2) Testosterone Cypionate 200mg/mL in Grapeseed Oil for IM Injection 3) Stanozolol 50 mg/mL The ISO 7 anteroom is being used by the film to gown up for sterile drug production. ...
Observation 8
There is no written testing program designed to assess the stability characteristics of diu g products.
Specifically,
Your stability programs are inadequate in that they did not include sterility testing at the end of products' shelf life to ensure that the chug products remain sterile throughout its shelf life. For example,
Meta PT Eye Drops Solution Lot# 112716 REDACTED (b)(4) with BUD of REDACTED (b)(4) storage condition.
A.
Meta PMK Eye Drops Lot# 022317 REDACTED (b)(4) with BUD of REDACTED (b)(4) storage condition.
B.
C. Testosterone Cypionate 200 mg/mL in Grapeseed Oil for IM Injection Lot # 041018sb with BUD of REDACTED (b)(4 ) storage condition.
Observation 9
Specifically, Yo
u fir, does not perform sterility and endotoxin testing on each lot of sterile diug product produced. For example,
A. Glutathione 20% Injection Lot # 112718 REDACTED (b)(6) was not tested for steri lity and endotoxin
prior to release.
B. Methylcobalamin (B12) 12.5 mg/mL IM Injection Lot # l 12718 REDACTED (b)(6) was not tested for s
terility and endotoxin prior to release.
C. Bi ot in 5mg/mL Solution for Injection Lot# 110718 REDACTED (b)(4) was not tested for sterility and endotoxin prior to release.
Observation 10
Testing and release of drug product for distribution do not include appropriate laboratory dete1mination o f satisfactory conformance to the final specifications and identity and strength of each active ingredient p rior to release. S
pecifically,
A. You firm does not perform potency testing on each lot of sterile diug products produced. For example, 1) Meta PT Eye Drops Solution Lot # 102918 REDACTED (b)(6) was not tested for potency prior to release. 2) Glutathione 20% Injection Lot# 112718 REDACTED (b)(6) was not tested for potency prior to release. 3) Methylcobalamin (B12) 12.5 mg/mL IM Injection was not tested for potency prior to release.
1) Meta PT Eye Drops Solution Lot # 102918'(6)(6I was not tested for potency prior to release.
2) Glutathione 20% Injection Lot# 112718'<bHSf was not tested for potency prior to release.
3) Methylcobalamin (B12) 12.5 mg/mL IM Injection was not tested for potency prior to release.
B.Your firm does not test the preservative content in the batches at the time of release. For example, 1) Meta PT Eye Drop Solution contains REDACTED (b)(4) as a preservative. 2) Glutathione 20% Injection contains REDACTED (b)(4) as a preservative. ...
Observation 11
Batch production and control records are not prepared for each batch of drug product produced and do not include complete information relating to the production and control of each batch.
Specifically,
Your firm did not create production records for Fentanyl Injection 50 mcg/mL produced at the facility. The commercially available fentanyl 2500 mcg/50 mL bottle was used to draw up REDACTED (b)(4) syringes as requested by the customer. There is no information as to what equipment and components were used for the batch.
Linked 483s whose text is not shown
- Dec 9, 2022: FDA document 176470: its numbered observations could not be read reliably from the PDF text.
- Feb 28, 2017: FDA document 103231: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 7546 | OSP | Meta Pharmacy Services, LLC | Las Vegas, NV | Active |
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054023118 | LICENSED PHARMACY | META PHARMACY SERVICES LLC | LAS VEGAS, NV | ACTIVE |
| 054021457 | LICENSED PHARMACY | META PHARMACY SERVICES LLC | LAS VEGAS, NV | CHANGE OF OWNERSHIP |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0004217 | NONRESIDENT PHARMACY | META PHARMACY SERVICES | LAS VEGAS, NV | ACTIVE (CURRENT) |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0013252 | Non Resident Pharmacy | Meta Pharmacy Services, LLC | LAS VEGAS, NV | Active |
| A9-0012952 | Non Resident Pharmacy | BARCLAY LUKE & PILLAI SPECIALTY PHARMACY PLLC | LAS VEGAS, NV | Expired |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301012981 | Pharmacy | Meta Pharmacy Services, LLC | Las Vegas, NV | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.